Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Knight Cancer Institute Study of Histology-Agnostic Immunotherapy With Focus on Timing: - Knight SHIFT - A Prospective, Multi-Histology Pragmatic Study

NCT07405086 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT07405086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07405086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Knight Cancer Institute Study of Histology-Agnostic Immunotherapy With Focus on Timing: - Knight SHIFT - A Prospective, Multi-Histology Pragmatic Study
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 4
Overall status
Recruiting
Start date
April 24, 2026
Completion date
December 31, 2028
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced biliary tract carcinoma, advanced head and neck squamous cell carcinoma, advanced hepatocellular carcinoma, advanced lung non-small cell carcinoma, advanced malignant solid neoplasm, advanced melanoma, advanced renal cell carcinoma, metastatic biliary tract carcinoma, metastatic head and neck squamous cell carcinoma, metastatic hepatocellular carcinoma, metastatic lung non-small cell carcinoma, metastatic malignant solid neoplasm, metastatic melanoma, metastatic renal cell carcinoma, recurrent head and neck squamous cell carcinoma, stage iii hepatocellular carcinoma ajcc v8, stage iii lung cancer ajcc v8, stage iii renal cell cancer ajcc v8, stage iv hepatocellular carcinoma ajcc v8, stage iv lung cancer ajcc v8, stage iv renal cell cancer ajcc v8